Scientific publications

Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy

Alfonso Gurpide (a), Belen Sádaba (b), Salvador Martín-Algarra (a), José R. Azanza (b), José M. Lopez-Picazo (a), Miguel A. Campanero (b), Juan P. Cabello (a), Isabel Gil-Aldea (b), Susana de la Cruz (a), Victor Fernández Gallego (b), Carmen Reyna (b), Clara Olier Garate (a), A J. Blanco-Prieto (b), Jaime Ceballos (a), Jesús García-Foncillas (a), Jose L Pérez-Gracia (a)
(a) Oncology Department and (b) Clinical Pharmacology Department, Clinica Universitaria de Navarra, University of Navarra, Navarra, Spain

Magazine: The Oncologist

Date: Sep 1, 2007

Clinical Pharmacology [SP] Clinical Research Unit [SP] Medical Oncology

5-HT3-receptor antagonists are one of the mainstays of antiemetic treatment, and they are administered either i.v. or orally. Nevertheless, sometimes neither administration route is feasible, such as in patients unable to admit oral intake managed in an outpatient setting. Our objective was to evaluate the bioavailability of s.c. granisetron.

Patients receiving platinum-based chemotherapy were randomized to receive 3 mg of granisetron either s.c. or i.v. in a crossover manner during two cycles. Blood and urine samples were collected after each cycle. Pharmacokinetic parameters observed with each administration route were compared by analysis of variance.

From May to November 2005, 31 patients were included and 25 were evaluable. Subcutaneous granisetron resulted in a 27% higher area under the concentration-time curve for 0-12 hours (AUC(0-12h)) and higher levels at 12 hours, with similar values for AUC(0-24h). The maximum concentration was lower with the s.c. than with the i.v. route and was observed 30 minutes following s.c. administration.

Granisetron administered s.c. achieves complete bioavailability. This is the first study that shows that s.c. granisetron might be a valid alternative to i.v. delivery. Further trials to confirm clinical equivalence are warranted. This new route of administration might be especially relevant for outpatient management of emesis in cancer patients.

CITATION  Oncologist. 2007 Sep;12(9):1151-5

you maybe interested


The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra


The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra


Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra